… ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform LEIDEN, Netherlands & … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the …
… Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, 2018 … collaboration we will explore a novel application of our Axiomer® technology to Galapagos’ fibrosis targets,” said …
… R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program … the unmet need in DEB and the current treatment landscape. Axiomer®: ProQR will introduce its novel, proprietary RNA …
… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, … 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR … (Nasdaq:PRQR), today announced that a presentation titled “Axiomer ® Technology: Therapeutic Oligonucleotides for …
… Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of …
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
